Barclays: Buy Seattle Genetics' Overlooked Pipeline, Stock Has 57% Upside
February 04, 2016 at 09:15 AM EST
Seattle Genetics, Inc. (NASDAQ: SGEN) share are down 28 percent since January 4. Barclays’ Jonathan Eckard initiated ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.